Search Within

Population Sciences Research Program

  1. "Lymphoma"
  2. "Center for Hematologic Malignancies"
  3. "Hematological Oncology"
Formats
  1. Meeting Abstract (36)
  2. Journal Article (2)
Groups
  1. Center for Hematologic Malignancies (38)
  2. Department of Medicine (38)
  3. Hematologic Malignancies, Division of (38)
  4. Lymphoma (38)
  5. Survivorship Research (14)
  6. Epidemiology and Biostatistics (11)

More Groups

People
  1. Steven Horwitz (38)
  2. Alison Moskowitz (15)
  3. David Straus (12)
  4. Anita Kumar (11)
  5. Ariela Noy (11)
  6. Andrew Zelenetz (10)

More People

Years
  1. 2023 (7)
  2. 2022 (1)
  3. 2021 (7)
  4. 2019 (12)
  5. 2017 (11)
Publications
  1. Hematological Oncology (38)
Publishers
  1. Wiley Blackwell (38)

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II‐IV peripheral T‐cell lymphoma: Phase II results
    Meeting Abstract

    Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL)
    Meeting Abstract

    Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Risk of breast implant associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants
    Meeting Abstract

    Ghione, P.; Cordeiro, P. G.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: Rationale for the phase 2 PRIMO trial
    Meeting Abstract

    Horwitz, S. M.; Foss, F. M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M. S.; Kim, Y. H.; Weinstock, D.; Lustgarten, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
    Journal Article

    Pro, B.; Horwitz, S. M.; Prince, H. M.; Foss, F. M.; Sokol, L.; Greenwood, M.; Caballero, D.; Morschhauser, F.; Wilhelm, M.; Iyer, S. P.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Interim data from the first clinical study of ADCT-301, a novel pyrrolobenzodiazapine-based antibody drug conjugate, in relapsed/refractory Hodgkin/non-Hodgkin lymphoma
    Meeting Abstract

    Horwitz, S. M.; Fanale, M. A.; Spira, A. I.; Havenith, K.; He, S.; Feingold, J. M.; Hamadani, M.
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium
    Meeting Abstract

    Lunning, M.; Horwitz, S.; Mehta-Shah, N.; Moskowitz, A.; Advani, R.; Beaven, A.; Haverkos, B.; Lechowicz, M.; Oki, Y.; Zain, J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save